Advaxis (NASDAQ: ADXS ) and AstraZeneca 's (NYSE: AZN ) MedImmune establish a clinical trial collaboration to evaluate the safety and efficacy of MedImmune's investigational
LONDON, July 22 (Reuters) - AstraZeneca is casting its net wider in the hot cancer immunotherapy field through a clinical trial collaboration with U.S. biotech firm Advaxis that will test drugs from both companies in combination.
NYSE: SYK ) has been mentioned as a potential suitor for Smith& Nephew. Pfizer (NYSE: PFE ) may make another run at AstraZeneca (NYSE: AZN ) after the end of the cool-off period. Post your comment!
(Corrects paragraph 7 to show failed bid for AstraZeneca happened in May not June))
(Corrects 6th paragraph to show Pfizer's failed bid for AstraZeneca happened in May not June)
secret that Pfizer (NYSE: PFE ) has had a rocky first half this year. The difficulties around its attempt to acquire AstraZeneca (NYSE: AZN ) were compounded by Q1 sales that missed market expectations by 9 percent. As it had announced last October
Considering Walgreen (NYSE: WAG ) and its plans to move to Switzerland , Pfizer's (NYSE: PFE ) failed bid for UK-based AstraZeneca (NYSE: AZN ), and now Medtronic's (NYSE: MDT ) acquisition of Ireland-based Covidien (NYSE: COV ), it's
t going to really reap those benefits very much. We saw [TICKER:PFE] Pfizer walk away from that [TICKER:AZN] AstraZeneca deal because of valuation concerns. I think AbbVie will have to be somewhat disciplined, to not keep chasing this forever
followed our recommendation to buy Novartis ( NVS ) and AstraZeneca ( AZN ), have done very well indeed. Novartis is up ..... dividend of $2.53 last year and $2.71 this year. AstraZeneca has done even better, up by 56% (from $48.24 to
having another go at merging with AstraZeneca ( AZN ), I was skeptical that ..... outcome to the one in January. AstraZeneca 's quick rejection following Pfizer ..... Pfizer had made their offer, before AstraZeneca started a charm offensive to convince